Enzo Biochem Collects $7 Million from Court Approved Escrow Fund Closings
Get Alerts ENZ Hot Sheet
Join SI Premium – FREE
NEW YORK--(BUSINESS WIRE)-- Enzo Biochem, Inc. (NYSE: ENZ) and wholly-owned Enzo Life Sciences, Inc. (together Enzo) today announced that Enzo has received $7.0 million previously held in escrow relating to the PerkinElmer and Molecular Probes settlements. This amount will be recognized by Enzo as a Legal Settlement gain in its Consolidated Statement of Operations for the quarter ended January 31, 2016.
Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses are dependent on a number of factors outside of the control of the company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2015. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160126005137/en/
For Enzo Biochem, Inc.
Anreder & Company
Steven
Anreder, 212-532-3232
[email protected]
or
CEOcast,
Inc.
Michael Wachs, 212-732-4300
[email protected]
Source: Enzo Biochem, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Spar Nord repays Tier 2 capital with ISINs DK0030431341 and DK0030432075
- PCI Biotech Holding ASA - Annual Report 2023
- Yara reports increased deliveries, lower prices and reduced GHG emission intensity in 1Q
Create E-mail Alert Related Categories
Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!